Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer

By M. Telli, K. Timms, J. Reid, Bryan T. J. Hennessy, Gordon B. Mills, K. Jensen, Zoltan Szallasi, William T. Barry, E. Winer, N. Tung and 15 more. Clinical Cancer Research, 2016

852 citations recorded by the source corpus.

Subfields: Genetics, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/9b31cf7f74a6f3020343bbba31e294ef36531aae

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Genetics

1. Hui Shen
2. C. Lord
3. Peter W. Laird
4. Alan Ashworth
5. Casey S. Greene
6. Christoph Bock
7. Sameer Quazi
8. M. Smulders

In Molecular Biology

1. C. Lord
2. Hui Shen
3. G. Way
4. Alan Ashworth
5. Casey S. Greene
6. Peter W. Laird
7. Mostafa Karimi
8. John N. Weinstein

In Oncology

1. C. Lord
2. Alan Ashworth
3. John N. Weinstein
4. Peter W. Laird
5. Mark J. O'Connor

Citations in the corpus

• Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas (2018, positive): “This extends the recognition of a bimodal distribution of HRD scores in breast and ovarian cancers and the enrichment of BRCA1/2 mutant or methylated cancers among HRD-high cancers that are more likely to respond to platinum-containing therapy (Telli et al., 2016).”
• PARP Inhibitors: The First Synthetic Lethal Targeted Therapy (2017, background): “genome of gBRCAm tumors - a BRCAness DNA scar, described above (55)).”